Group and all 16 neurological controls were seronegative (Table 1). The MFI was significantly higher in NMDAR patients (median 59,085, range 5,784 to 213,910) compared to neurological controls (median -1,239, range -3,751 to 2,169, Fig 4B). Thus, the sensitivity and specificity of the FACS assay Necrosulfonamide web werePLOS ONE | DOI:10.1371/journal.pone.0122037 March 27,6 /A Live Cell Based Assay for Detection of NMDAR AntibodiesFig 1. Immunofluorescence CBA with HEK293A cells transiently overexpressing functional NMDAR tagged with green fluorescent proteins. Staining pattern with NMDAR antibody positive (A-C) and negative (D) serum. HEK293A cells were transiently transfected to overexpress EmGFP-tagged NR1, NR2A and GFP-tagged NR2B, incubated with diluted human serum and NMDAR CEP-37440 dose antibodies were visualized by a Cy3-conjugated secondary antibody and counter-stained with DAPI to detect dead cells (left column: green fluorescence/EmGFP+GFP; middle column: red fluorescence/Cy3; right column: overlay of EmGFP/GFP, Cy3 and DAPI (A+D)). (B)+(C) Images show colocalization of NMDAR and serum NMDAR antibodies at high magnification (scale bars: 10 m). (B) NMDAR antibodies bound to surface of cells. (C) Bound NMDAR antibodies internalized by the cells. CBA = cell-based assay. DAPI = 4′,6-diamidino-2-phenylindole. (Em) GFP = journal.pone.0174109 (emerald) green fluorescent protein. NMDAR = N-methyl-D-aspartate receptor. doi:10.1371/journal.pone.0122037.gPLOS ONE | DOI:10.1371/journal.pone.0122037 March 27,7 /A Live Cell Based Assay for Detection of NMDAR AntibodiesFig 2. NMDAR IgG antibody titers and fpsyg.2016.00135 MFI values in the discovery group. (A) Using the CBA serum NMDAR IgG antibodies were exclusively detected in serum samples of patients with NMDAR encephalitis, but not in neurological and healthy controls. (B) In the FACS assay serum NMDAR IgG MFI levels were higher in patients with NMDAR encephalitis than in neurological and healthy controls, but one serum positive for NMDAR antibodies was missed with this method (shown in red). The cut-off MFI value of 20,700 is indicated by a dashed horizontal line. Antibody titers and MFI values were compared using a non-parametric test (Kruskal Wallis test) and overall p-values are shown in the graphs. Medians are indicated by horizontal bars. CBA = cell-based assay. MFI = delta median fluorescence intensity. FACS = fluorescence activated cell sorting. HC = healthy controls. NC = neurological controls. NMDAR-E = Nmethyl-D-aspartate receptor encephalitis. doi:10.1371/journal.pone.0122037.gequally high in the validation group (95 CI 61.7?8.5 and 79.4?00.0, respectively) as in the discovery group.Comparison of CBA and FACSThe concordance kappa value between CBA and FACS was 0.943 (p<0.0001). 85 samples were seronegative and 20 samples were seropositive with both methods. Three samples were seropositive in the CBA, but seronegative in the FACS assay. Correlation of antibody titers of the CBA with MFI obtained by FACS based analysis was 0.697 (Spearman's ; p<0.0001; Fig 5). To elucidate why three positive samples could not be detected in the FACS assay, we compared MFI and MFI values resulting from IgG binding to NMDAR and CD2 transfected cells alone. Whereas MFI and MFI values obtained by binding of IgG to NMDAR transfected cells were significantly (p<0.01) lower in false negative samples, MFI obtained by binding of IgG to CD2 transfected cells did not differ between the groups (S3 Fig). Therefore, missing of positive samples cannot be attributed to high back.Group and all 16 neurological controls were seronegative (Table 1). The MFI was significantly higher in NMDAR patients (median 59,085, range 5,784 to 213,910) compared to neurological controls (median -1,239, range -3,751 to 2,169, Fig 4B). Thus, the sensitivity and specificity of the FACS assay werePLOS ONE | DOI:10.1371/journal.pone.0122037 March 27,6 /A Live Cell Based Assay for Detection of NMDAR AntibodiesFig 1. Immunofluorescence CBA with HEK293A cells transiently overexpressing functional NMDAR tagged with green fluorescent proteins. Staining pattern with NMDAR antibody positive (A-C) and negative (D) serum. HEK293A cells were transiently transfected to overexpress EmGFP-tagged NR1, NR2A and GFP-tagged NR2B, incubated with diluted human serum and NMDAR antibodies were visualized by a Cy3-conjugated secondary antibody and counter-stained with DAPI to detect dead cells (left column: green fluorescence/EmGFP+GFP; middle column: red fluorescence/Cy3; right column: overlay of EmGFP/GFP, Cy3 and DAPI (A+D)). (B)+(C) Images show colocalization of NMDAR and serum NMDAR antibodies at high magnification (scale bars: 10 m). (B) NMDAR antibodies bound to surface of cells. (C) Bound NMDAR antibodies internalized by the cells. CBA = cell-based assay. DAPI = 4',6-diamidino-2-phenylindole. (Em) GFP = journal.pone.0174109 (emerald) green fluorescent protein. NMDAR = N-methyl-D-aspartate receptor. doi:10.1371/journal.pone.0122037.gPLOS ONE | DOI:10.1371/journal.pone.0122037 March 27,7 /A Live Cell Based Assay for Detection of NMDAR AntibodiesFig 2. NMDAR IgG antibody titers and fpsyg.2016.00135 MFI values in the discovery group. (A) Using the CBA serum NMDAR IgG antibodies were exclusively detected in serum samples of patients with NMDAR encephalitis, but not in neurological and healthy controls. (B) In the FACS assay serum NMDAR IgG MFI levels were higher in patients with NMDAR encephalitis than in neurological and healthy controls, but one serum positive for NMDAR antibodies was missed with this method (shown in red). The cut-off MFI value of 20,700 is indicated by a dashed horizontal line. Antibody titers and MFI values were compared using a non-parametric test (Kruskal Wallis test) and overall p-values are shown in the graphs. Medians are indicated by horizontal bars. CBA = cell-based assay. MFI = delta median fluorescence intensity. FACS = fluorescence activated cell sorting. HC = healthy controls. NC = neurological controls. NMDAR-E = Nmethyl-D-aspartate receptor encephalitis. doi:10.1371/journal.pone.0122037.gequally high in the validation group (95 CI 61.7?8.5 and 79.4?00.0, respectively) as in the discovery group.Comparison of CBA and FACSThe concordance kappa value between CBA and FACS was 0.943 (p<0.0001). 85 samples were seronegative and 20 samples were seropositive with both methods. Three samples were seropositive in the CBA, but seronegative in the FACS assay. Correlation of antibody titers of the CBA with MFI obtained by FACS based analysis was 0.697 (Spearman's ; p<0.0001; Fig 5). To elucidate why three positive samples could not be detected in the FACS assay, we compared MFI and MFI values resulting from IgG binding to NMDAR and CD2 transfected cells alone. Whereas MFI and MFI values obtained by binding of IgG to NMDAR transfected cells were significantly (p<0.01) lower in false negative samples, MFI obtained by binding of IgG to CD2 transfected cells did not differ between the groups (S3 Fig). Therefore, missing of positive samples cannot be attributed to high back.
